Search for: "GlaxoSmithKline LLC"
Results 1 - 20
of 179
Sort by Relevance
|
Sort by Date
29 Mar 2024, 10:04 am
GlaxoSmithKline Consumer Healthcare Holdings (US) LLC, --- F.Supp.3d ----, 2024 WL 348821, No: 4:20-cv-09077-JSW (N.D. [read post]
28 Feb 2024, 2:00 pm
GlaxoSmithKline LLC (9th Cir. 2017) 858 F.3d 1227, 1237 (Wendell) [“Perhaps in some cases there will be a plethora of peer reviewed evidence that specifically shows causation. [read post]
18 Jan 2024, 9:16 am
The Federal Circuit explicitly limited its holding in GlaxoSmithKline LLC v. [read post]
18 Dec 2023, 10:00 pm
Hear expert commentary from Tom Irving and Michelle O’Brien of the Marbury Law Group on the risk generic drug companies face when utilizing a skinny label in the aftermath of the Federal Circuit’s decision in Glaxosmithkline LLC v. [read post]
18 Dec 2023, 9:07 pm
§ 355(j)(2)(A)(viii) (the so-called "skinny label) has in the recent past raised something of a kerfuffle before the Federal Circuit (see "GlaxoSmithKline LLC v. [read post]
7 Dec 2023, 1:47 pm
I want to note here that the facts in this case are different from prior carve-out cases such as GlaxoSmithKline LLC v. [read post]
21 Jul 2023, 11:56 am
GlaxoSmithKline, 905 F.3d 694, 707 (3d Cir. 2018) that such an inquiry is fact-specific and requires the consideration of multiple factors. [read post]
18 May 2023, 8:01 am
GlaxoSmithKline LLC, involving an undoubtedly important and recurring issue involving drug labeling and inducement of patent infringement. [read post]
15 May 2023, 10:14 am
GlaxoSmithKline, LLC, which has come to be known as the “skinny label” case. [read post]
15 May 2023, 9:59 am
GlaxoSmithKline LLC, which presented the question: "If a generic drug's FDA-approved label carves out all of the language that the brand manufacturer has identified as covering its patented uses, can the generic manufacturer be held liable on a theory that its label still intentionally encourages infringement of those carved-out uses? [read post]
15 May 2023, 8:13 am
GlaxoSmithKline LLC, and in some ways the only positive outcome is that the Court has shown it is willing to refuse to take action is cases other than subject matter eligibility (although Justice Kavanaugh indicated he would have granted the petition). [read post]
15 May 2023, 7:21 am
GlaxoSmithKline LLC. [read post]
11 May 2023, 1:16 pm
GlaxoSmithKline LLC. [read post]
1 May 2023, 10:11 am
GlaxoSmithKline LLC, No. 22-37: This case examines whether FDA-required labeling in a “skinny-label” situation can be considered patent infringement. [read post]
22 Dec 2022, 7:59 am
GlaxoSmithKline LLC, No. 22-37, has a good chance of being heard by the Court, although it may be better for Congress to work to resolve the pending questions. [read post]
17 Oct 2022, 11:27 am
Glaxosmithkline LLC, 981 F.3d 1030, 1040 (Fed. [read post]
26 Sep 2022, 4:49 am
GlaxoSmithKline LLC, No. 22-37 This case delves deeply into the patent-FDA overlap and involves an increasingly common situation “skinny label” situation. [read post]
29 Jul 2022, 6:11 pm
GlaxoSmithKline, LLC 22-37Issue: Whether a generic drug manufacturer’s FDA-approved label that carves out all of the language the brand manufacturer has identified as covering its patented uses can be held liable on a theory that its label still intentionally encourages infringement of those carved-out uses. [read post]
17 Jul 2022, 5:00 am
GlaxoSmithKline LLC, SCT Docket No. 22-37 (2022). [read post]
6 May 2022, 8:10 am
Cir. 2021), en banc denied at GlaxoSmithKline LLC v. [read post]
